肺癌藥物市場按治療類型、給藥方法、治療線、分期、處方狀態、分銷管道、癌症類型和最終用戶分類－2025-2032 年全球預測

預計到 2032 年肺癌藥物市場規模將成長至 598.9 億美元，複合年成長率為 8.70%。

主要市場統計數據
基準年2024年	307億美元
預計2025年	332.3億美元
預測年份：2032年	598.9億美元
複合年成長率（%）	8.70%

全面介紹影響肺癌治療創新和交付的不斷發展的科學、臨床和衛生系統動態

由於持續的臨床需求、快速的科學進步以及不斷變化的監管和報銷格局，肺癌治療在腫瘤學中佔據著舉足輕重的地位。近年來，肺癌治療已從千篇一律的細胞毒性療法轉變為利用標靶治療和免疫調節的精準醫療模式。這種轉變得益於對腫瘤分子特徵的更深入研究、伴隨診斷的廣泛應用以及更精細的臨床試驗設計，這些設計加快了治療方法檢驗並最佳化了患者選擇。

此外，臨床界越來越關注結合全身和局部干預的多藥物聯合治療，旨在改善存活結果的同時維持生活品質。醫療保健系統和付款方正在適應長期治療途徑，這引發了關於價值、可負擔性和公平獲取的新問題。因此，產業、臨床實踐和政策層面的相關人員正在重新評估開發策略和商業模式，以確保科學前景與現實世界交付的一致性。在此背景下，仔細獎勵臨床證據、監管訊號、供應鏈韌性和相關人員，對於引導下一波投資和打入市場策略至關重要。

分子特徵、聯合免疫腫瘤學方法以及監管適應症的重大變化正在重新定義肺癌治療策略

在科學突破、監管變革和治療模式轉變的共同推動下，肺癌治療領域正經歷一場變革性的轉變。分子腫瘤學的進步已將可操作的標靶擴展到經典的驅動突變之外，而次世代定序儀和液態切片技術則使得早期準確地檢測可操作的生物標記成為可能。同時，免疫腫瘤學已發展成為一種精細的組合策略，查核點抑制劑與標靶藥物、抗體藥物複合體或新型免疫調變器相結合，試圖將持久應答者轉化為更大規模的患者群體。

監管機構也不斷調整，提供快速且適應性強的核准途徑，獎勵具有臨床意義的改進，並促進與真實世界證據生成相關的有條件核准。付款人框架開始納入基於結果的合約和特定適應症的定價，以管理長期成本風險。在研發方面，製藥和生物技術公司正在深化與診斷開發商、委外研發機構和專業服務供應商的合作，以簡化開發時間表並共同部署診斷和藥物。因此，競爭差異化日益受到綜合證據包、可擴展生產和靈活商業化策略的驅動，這些策略考慮到了異質性患者群體和多樣化的醫療保健環境。

2025 年美國關稅如何重塑肺癌治療領域的供應鏈架構、製造決策和籌資策略的綜合分析

2025年美國關稅的累積效應正在為整個肺癌治療價值鏈帶來新的複雜性，影響製造成本、供應鏈設計和籌資策略。針對原料、原料藥和專用設備的關稅調整，正在獎勵申辦方和製造外包重新評估其地理佈局和供應商組合。為此，許多公司已啟動雙重採購策略並加強與供應商的夥伴關係，以降低集中化帶來的脆弱性，並保持關鍵試劑和組件流通的連續性。

除了直接的成本影響外，關稅還加速了圍繞在岸生產和區域製造能力的討論，以此作為縮短前置作業時間和降低跨境貿易波動風險的手段。此類策略措施通常需要大量的資本配置和監管協調，尤其是在遷移無菌注射劑和生物製藥製造地時。因此，一些開發人員優先考慮流程整合和模組化製造技術，以實現靈活性，而無需完全遷移營運。

此外，關稅也會對輔助服務產生連鎖反應，例如診斷試劑的生產以及支援治療管理和監測的醫療設備供應鏈。衛生系統正在調整其採購實踐，以平衡短期預算壓力和長期韌性，通常是透過與製造商協商長期合約或利用關鍵投入的策略性庫存。總的來說，這些調整凸顯了供應治療方法透明度、情境規劃以及與海關和貿易專家密切合作的重要性，以便在不斷變化的關稅環境中保持專案時間表和患者可及性。

治療方式、治療線、腫瘤類型、給藥途徑和分銷管道的詳細細分洞察決定了開發和獲取

準確了解細分市場動態對於將開發和商業策略與臨床現實和交付管道結合至關重要。在治療方法分析治療方法方法時，重要的是要考慮化療、免疫療法、放射線治療和標靶治療的不同發展路徑和臨床效用。化療，包括烷化劑、鉑類化合物、紫杉烷和拓樸異構酶抑制劑，在聯合和序貫聯合治療中各佔一席之地，並在特定方案中發揮重要作用。免疫療法包括檢查點抑制劑，例如 CTLA-4 抑制劑、PD-1 抑制劑和 PD-L1 抑制劑，具有不同的機制、給藥方法和生物標記依賴性。放射放射線治療仍然是一種重要的局部治療方法，包括近距離放射治療、體外放射治療和立體定位放射治療，每種治療都有不同的適用性，取決於腫瘤位置和治療目標。查核點標靶治療擴大分子標靶進行分層，例如 ALK 抑制劑、BRAF 抑制劑、EGFR 抑制劑和 ROS1 抑制劑，這需要開發伴隨診斷和抗藥性管理策略。

治療線細分揭示了臨床開發和商業化的策略曲折點。輔助和新輔助適應症需要強大的轉換終點和已證實的長期療效，而一線、維持、二線、三線及以上適應症則需要在安全性、耐久性和序列相容性方面進行明確區分。早期候選藥物的區分通常可以實現更廣泛的應用，但也需要頭對頭和可操作的比較證據。在肺癌亞型中，非小細胞肺癌和小細胞肺癌有不同的生物學行為和治療方法。 NSCLC 受益於豐富的標靶環境和對免疫療法的反應性，而 SCLC 則需要注重全身性聯合治療和早期檢測策略。

吸入、注射和口服等給藥形式的考慮因素會影響患者的依從性、臨床經濟學和分銷物流。口服製劑可以促進門診病人的依從性並減少輸液資源的壓力，但需要監測依從性並考慮藥物交互作用。吸入給藥可提供所選治療方法的局部暴露，但取決於設備相容性和付款人的接受度。注射劑，尤其是生技藥品和 ADC，需要輸液基礎設施和低溫運輸物流。最後，醫院藥局、線上藥局、零售藥局和專科診所之間的分銷管道細分會影響取得途徑和報銷談判點。每個管道都有獨特的合約動態和對患者援助計劃的影響，而專科診所通常充當複雜治療管理和監測的中心。這些細分結合起來，為臨床項目優先排序、供應策略和商業性參與計劃提供資訊，以符合臨床效用和醫療服務提供實際情況。

亞太、歐洲和中東地區的關鍵區域動態將影響治療可近性、報銷和分銷策略

區域動態對監管時間表、報銷框架和商業性實施策略有重大影響。在美洲，監管機構和付款人高度重視比較有效性和基於價值的安排，公立和私立醫療體系的採用模式各不相同。該地區通常在新型標靶治療和免疫療法的快速採用方面處於領先地位，但面臨著付款人主導的藥物利用管理和價格談判的壓力，需要強力的健康經濟證據和患者支持計劃。

歐洲、中東和非洲地區的監管途徑和報銷方式差異巨大。西方市場通常需要全面的衛生技術評估和真實世界證據，而該地區新興市場的可負擔性和可近性項目可能更具優先地位。監管協調工作和跨境臨床合作對於實現藥物開發規模化和核准後證據生成變得越來越重要。中東和非洲地區既充滿機遇，也面臨複雜性，其基礎建設多樣、疾病負擔報告差異化，採購模式也各有不同，需要採取靈活的市場進入策略。

亞太地區呈現出多元化的格局，其快速應用受到區域監管改革、國內製造能力和國家癌症控制重點的推動。該地區一些國家正在透過與真實世界證據相關的條件性途徑加速標靶治療藥物和免疫療法的核准，而其他國家則保持嚴格的本地臨床要求。此外，在擴大基因組檢測和分散式醫療服務方面也取得了進展，重塑了患者識別和治療的進程。總而言之，這些區域差異凸顯了製定量身定做的證據策略、彈性價格設定以及應對監管和基礎設施多樣性的供應鏈設計的需求。

策略競爭概述強調了整合的產品組合、創新的生物技術產品線和合作夥伴生態系統，加速了肺癌治療的進展

肺癌治療領域的競爭格局特徵是大型製藥企業、致力於推進新治療方法的生物技術公司以及支持快速開發和商業化的專業服務供應商的混合。市場領導者往往透過整合後期資產、深厚的研發管線和成熟的商業基礎設施，從而實現差異化競爭。這些公司通常利用其全球監管經驗和付款人參與能力來加速產品上市，並將自己定位為治療替代藥物。

規模較小的生物技術公司和大學衍生公司正在為創新做出重大貢獻，尤其是在雙特異性抗體、抗體藥物複合體和細胞療法等新型治療方法。這些公司通常會與主要贊助商建立策略聯盟或選擇性共同開發契約，以確保開發和商業規模。同時，診斷開發商是伴隨檢測和生物標記主導的臨床策略的關鍵合作夥伴。競爭對手的成功越來越取決於他們能否提供整合的證據、建立靈活的商業模式，並在不同的醫療保健體系中展現其實際效用。

為開發商和商業團隊提供可行的策略要務，以協調生物標記主導的開發、供應彈性和付款人就緒證據的生成

產業領導者應優先考慮一系列可行的舉措，以應對臨床複雜性、供應鏈中斷和付款人需求。首先，將開發項目與強大的生物標記策略和伴隨診斷相結合，可以改善患者選擇，並強化對付款人和臨床醫生的價值提案。早期投資於轉化研究和自適應試驗設計可以縮短開發週期，並與標準治療藥物進行更清晰的區分。其次，透過多元化採購、區域製造夥伴關係和模組化生產技術來建立供應鏈彈性，有助於滿足交貨期限，同時降低與關稅和中斷相關的風險。

第三，商業團隊應設計證據產生計劃，包括真實世界數據收集、健康經濟模型和基於結果的合約選項，以解決付款人對長期價值的擔憂。關鍵意見領袖和多學科護理中心的早期參與可以促進指南的納入和適當的採用。第四，最佳化患者支援和依從性計劃（尤其是口服和門診藥物）將促進保留和療效，並需要與數位工具和專業藥房網路整合。最後，公司應考慮彈性價格設定和可及性策略，以反映區域負擔能力的限制，並透過利用分級合約、同情用藥夥伴關係以及與公共和非營利利益相關人員的策略夥伴關係來促進公平可及性。總之，這些行動為將科學進步轉化為永續的臨床和商業性影響提供了切實可行的藍圖。

一種透明的調查方法，結合文獻綜述、專家意見和跨學科證據綜合，以支持可行的結論和決策

本分析所依據的調查方法結合了系統性的文獻回顧、專家訪談和跨部門證據三角檢驗，以確保獲得可靠且可操作的見解。本研究審查了同行評審的臨床數據、監管指南文件和公共衛生建議，以支持臨床和監管解釋。此外，來自臨床醫生、藥物經濟學家、供應鏈專家和診斷開發人員的主要定性意見，為實施、病患路徑和報銷動態提供了實用見解。

調查方法強調整合臨床前機制理解、臨床試驗結果與真實世界臨床實務模式的證據。分析技術包括治療類別的比較評估、供應鏈緊急情境規劃以及商業模式的定性評估。透過與領域專家的研討會檢驗假設，並注意交叉引用已發表的監管資訊和政策解讀。限制包括快速發展的臨床證據和政策環境；本調查方法透過鼓勵定期更新和逐步深化與主要監管和臨床拐點相關的研究來解決這些限制。

科學創新、營運彈性和付款人一致的證據策略的相互作用對於維持患者影響至關重要

總而言之，肺癌治療正處於一個十字路口，科學發展勢頭必須與營運靈活性和相關人員一致的價值展示相匹配。分子標靶治療、免疫腫瘤學和診斷技術的進步拓展了治療的可能性，但成功的商業化取決於將這些進步轉化為可及且永續的治療途徑。供應鏈中斷和貿易政策的轉變凸顯了韌性規劃的重要性，而付款方的期望也越來越要求全面的現實世界證據和以結果為導向的合約。

展望未來，將生物標記主導的研發與靈活的生產、區域可及性策略以及以付款人為導向的證據計劃相結合的相關人員，將最有能力將臨床創新轉化為對患者有意義的影響。在臨床、監管、商業和供應鏈領域保持密切合作，將有助於各機構應對複雜情況，並加速將有前景的治療方法轉化為改善肺癌患者預後的標準治療方案。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 透過探索 PD-1 和 PD-L1 以外的新查核點靶點，擴大肺癌免疫治療適應症
• 人工智慧驅動的放射組學和基因組學整合，用於肺癌治療中的預測性生物標記識別
• 一種新型雙特異性抗體方法針對兩種致癌途徑治療非小細胞肺癌（NSCLC）
• 引入液態生物檢體檢測，用於個人化監測肺癌治療反應
• 開發新型 KRAS G12C 抑制劑和聯合治療以克服非小細胞肺癌 (NSCLC) 的抗藥性
• 基於吸入奈米載體的藥物輸送系統在標靶治療中的進展
• EGFR外顯子20插入突變治療及NSCLC臨床試驗結果日益重要
• 採用真實世界證據框架加速肺癌治療途徑的監管核准
• TCR-T細胞和NK細胞在晚期肺癌治療的應用
• 專注於克服標靶治療和免疫治療中的抗藥性機制

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章肺癌藥物市場依治療類型

• 化療
  • 烷化劑
  • 鉑金基地
  • 紫杉烷類
  • 拓樸異構酶抑制劑
• 免疫療法
  • CTLA-4抑制劑
  • PD-1抑制劑
  • PD-L1抑制劑
• 放射治療
  • 近距離放射治療
  • 體外照射
  • 立體定位放射治療
• 支持性護理
  • 止吐藥
  • 骨骼改質劑
  • 造血生長因子
• 外科手術
• 標靶治療
  • 間變性淋巴瘤激酶（ALK）抑制劑
  • BRAF抑制劑
  • EGFR抑制劑

9. 按給藥方式分類的肺癌藥物市場

• 吸入
• 注射
• 口服

10. 肺癌藥物市場治療線

• 一線
• 第二行
• 三線及以後

第11章肺癌藥物市場（依疾病階段）

• 第一階段
• 第二階段
• 第三階段
• 第四階段

第12章肺癌藥物市場（依處方箋狀況）

• 品牌
• 非專利的

第13章肺癌藥物市場（按分銷管道）

• 線下零售
• 網路零售

第14章肺癌治療藥物市場（依癌症類型）

• 非小細胞肺癌（NSCLC）
  • 腺癌
  • 大細胞癌
  • 鱗狀細胞癌
• 小細胞肺癌（SCLC）

第15章肺癌藥物市場（依最終用戶）

• 門診輸液中心
• 癌症中心
• 居家照護環境
• 醫院

第16章肺癌藥物市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第17章肺癌藥物市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第18章 肺癌藥物市場（依國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第19章 競爭態勢

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited

The Lung Cancer Therapeutics Market is projected to grow by USD 59.89 billion at a CAGR of 8.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 30.70 billion
Estimated Year [2025]	USD 33.23 billion
Forecast Year [2032]	USD 59.89 billion
CAGR (%)	8.70%

Comprehensive introduction to the evolving scientific, clinical, and health system dynamics shaping lung cancer therapeutic innovation and delivery

Lung cancer therapeutics occupy a pivotal position within oncology due to persistent clinical need, rapid scientific advances, and evolving regulatory and reimbursement landscapes. Recent years have seen a shift from one-size-fits-all cytotoxic approaches toward precision medicine paradigms that harness targeted therapies and immune modulation. This transformation is underpinned by deeper molecular characterization of tumors, broader adoption of companion diagnostics, and more sophisticated clinical trial designs that accelerate therapeutic validation while refining patient selection.

Moreover, the clinical community is increasingly focused on integrating multimodal regimens that combine systemic agents with localized interventions, aiming to improve survival outcomes while preserving quality of life. Health systems and payers are adapting to long-term treatment pathways that raise new questions about value, affordability, and equitable access. Consequently, stakeholders across industry, clinical practice, and policy are re-evaluating development strategies and commercial models to align scientific promise with real-world delivery. In this context, careful synthesis of clinical evidence, regulatory signals, supply chain resilience, and stakeholder incentives becomes essential for guiding next-wave investments and market entry strategies.

High-impact shifts in molecular characterization, combination immuno-oncology approaches, and regulatory adaptation that are redefining therapeutic strategies for lung cancer

The landscape of lung cancer therapeutics is experiencing transformative shifts driven by convergence of scientific breakthroughs, regulatory evolution, and changing care paradigms. Advances in molecular oncology have expanded actionable targets beyond classical driver mutations, while next-generation sequencing and liquid biopsy technologies have enabled earlier and more accurate detection of actionable biomarkers. At the same time, immuno-oncology has matured into nuanced combination strategies that seek to convert durable responders into a larger patient cohort by pairing checkpoint inhibitors with targeted agents, antibody-drug conjugates, or novel immune modulators.

Regulatory bodies are also adapting, offering accelerated and adaptive pathways that reward clinically meaningful improvements and facilitate conditional approvals tied to real-world evidence generation. Payer frameworks are beginning to incorporate outcomes-based contracting and indication-specific pricing to manage long-term cost exposure. Operationally, pharmaceutical and biotech companies are forging deeper collaborations with diagnostic developers, contract research organizations, and specialized service providers to streamline development timelines and ensure diagnostic-drug co-deployment. As a result, competitive differentiation increasingly depends on integrated evidence packages, scalable manufacturing, and flexible commercialization strategies that account for heterogeneous patient populations and diverse care settings.

Integrated analysis of how 2025 United States tariff measures are reshaping supply chain architectures, manufacturing decisions, and procurement strategies across lung cancer therapeutics

The cumulative effects of tariff actions originating in the United States in 2025 have introduced new layers of complexity across the lung cancer therapeutics value chain, influencing production costs, supply chain design, and sourcing strategies. Tariff adjustments that apply to raw materials, active pharmaceutical ingredients, and specialized equipment have created incentives for sponsors and contract manufacturing partners to reassess geographic footprints and supplier portfolios. In response, many organizations have initiated dual-sourcing strategies and closer supplier partnerships to mitigate single-point vulnerabilities and preserve continuity of critical reagent and component flows.

Beyond direct cost implications, tariffs have accelerated conversations around onshoring and regional manufacturing capacity as a means to shorten lead times and reduce exposure to cross-border trade volatility. Such strategic moves typically require significant capital allocation and regulatory alignment, particularly when relocating sterile injectable or biologic drug production. Consequently, some developers have prioritized process intensification and modular manufacturing technologies to achieve flexibility without fully relocating operations.

Additionally, tariffs have ripple effects on ancillary services, including diagnostic test production and medical device supply chains that support therapeutic administration and monitoring. Health systems are adapting procurement practices to balance near-term budgetary pressures against long-term resilience, often negotiating longer-term contracts with manufacturers or leveraging strategic inventories for critical inputs. In aggregate, these adjustments emphasize the importance of supply chain transparency, scenario planning, and close engagement with customs and trade specialists to maintain program timelines and patient access in a shifting tariff environment.

In-depth segmentation insights across therapeutic modalities, lines of care, tumor types, administration routes, and distribution channels shaping development and access

A nuanced understanding of segment-level dynamics is essential for aligning development and commercial strategies with clinical realities and delivery channels. When therapies are analyzed by therapy type, it is important to consider the distinct developmental pathways and clinical utility of chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy retains a foundational role in certain regimens, with alkylating agents, platinum-based compounds, taxanes, and topoisomerase inhibitors each occupying defined niches in combination and sequential approaches. Immunotherapy encompasses checkpoint blockade modalities such as CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, which vary in mechanism, dosing paradigms, and biomarker dependencies. Radiation therapy remains a critical local modality and includes brachytherapy, external beam radiation, and stereotactic body radiation, each offering differential applicability based on tumor location and intent of care. Targeted therapy is increasingly stratified by molecular targets, including ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, which demand companion diagnostic alignment and resistance-management strategies.

Line-of-therapy segmentation reveals strategic inflection points for clinical development and commercialization. Adjuvant and neoadjuvant settings require robust translational endpoints and longer-term outcome demonstration, while first-line, maintenance, second-line, and third-line-and-beyond indications demand clear differentiation on safety, durability, and sequencing compatibility. Differentiating a candidate in early lines often unlocks broader adoption but also requires head-to-head or pragmatic comparative evidence. When classifying by type of lung cancer, non-small cell lung cancer and small cell lung cancer present divergent biological behaviors and therapeutic modalities; NSCLC benefits from a rich targetable landscape and immunotherapy responsiveness, whereas SCLC requires intensified focus on systemic combinations and early detection strategies.

Mode-of-administration considerations-whether inhalation, injectable, or oral-shape patient adherence, site-of-care economics, and distribution logistics. Oral agents facilitate outpatient continuity and can reduce infusion resource burden, but raise adherence monitoring and drug-drug interaction considerations. Inhalation delivery offers localized exposure for select therapeutic modalities but depends on device compatibility and payer acceptance. Injectable therapeutics, particularly biologics and ADCs, demand infusion infrastructure and cold-chain logistics. Finally, distribution channel segmentation spanning hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics influences access pathways and reimbursement negotiation points. Each channel has unique contracting dynamics and patient support program implications, with specialty clinics often central to complex therapy administration and monitoring. Taken together, these segmentation lenses inform prioritization of clinical programs, supply strategies, and commercial engagement plans that align with clinical utility and care delivery realities.

Critical regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory access, reimbursement, and distribution strategies for therapeutics

Regional dynamics exert strong influence on regulatory timelines, reimbursement frameworks, and commercial execution strategies. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and value-based arrangements, with heterogeneous adoption patterns across public and private systems. This region often leads in rapid adoption of novel targeted agents and immunotherapies but faces pressure from payer-driven utilization management and pricing negotiations that necessitate robust health economic evidence and patient support programs.

Across Europe, the Middle East, and Africa, regulatory pathways and reimbursement approaches vary widely. Western European markets typically demand comprehensive health technology assessments and real-world evidence, while emerging markets in the region may prioritize affordability and access programs. Regulatory harmonization efforts and cross-border clinical collaborations are increasingly important for achieving scale in drug development and post-approval evidence generation. The Middle East and Africa present both opportunity and complexity due to variable infrastructure, heterogeneous disease burden reporting, and different procurement models that require adaptive market-entry tactics.

The Asia-Pacific region represents a diverse landscape where rapid adoption can hinge on local regulatory reforms, domestic manufacturing capacity, and national cancer control priorities. Several countries in the region are accelerating approvals for targeted therapies and immunotherapies through conditional pathways tied to real-world evidence, while others maintain stringent local clinical requirements. Additionally, evolving initiatives to expand genomic testing and decentralized care delivery are reshaping patient identification and treatment uptake. Collectively, these regional nuances highlight the need for geographically tailored evidence strategies, flexible pricing arrangements, and supply-chain designs that accommodate regulatory and infrastructural diversity.

Strategic competitive overview emphasizing integrated portfolios, biotech innovation pipelines, and partner ecosystems that accelerate lung cancer therapeutic advancement

The competitive landscape in lung cancer therapeutics is characterized by a blend of large pharmaceutical companies, biotechs advancing novel modalities, and specialized service providers that enable rapid development and commercialization. Market leaders tend to differentiate through integrated portfolios that combine late-stage assets, pipeline depth, and established commercial infrastructure. These organizations often leverage global regulatory experience and payer engagement capabilities to accelerate launches and secure place-in-therapy positions.

Smaller biotechs and academic spinouts contribute disproportionate innovation, particularly in emerging modalities such as bispecific antibodies, antibody-drug conjugates, and cell-based therapies. These entities frequently pursue strategic partnerships or selective co-development agreements with larger sponsors to access development and commercial scale. Contract research and manufacturing partners play an instrumental role in enabling flexible development timelines and managing biologics complexity, while diagnostics developers are critical collaborators for companion assays and biomarker-driven clinical strategies. Across the competitive set, success increasingly depends on integrated evidence generation, adaptable commercial models, and the ability to demonstrate real-world benefit in diverse health system contexts.

Actionable strategic imperatives for developers and commercial teams to align biomarker-driven development, supply resilience, and payer-ready evidence generation

Industry leaders should prioritize a set of actionable initiatives to navigate clinical complexity, supply-chain disruption, and payer demands. First, aligning development programs with robust biomarker strategies and companion diagnostics will improve patient selection and strengthen value propositions for payers and clinicians. Investing early in translational research and adaptive trial designs can shorten development cycles and create clearer differentiation against standard-of-care comparators. Secondly, building supply-chain resilience through diversified sourcing, regional manufacturing partnerships, and modular production technologies will mitigate tariff- and disruption-related risks while preserving delivery timelines.

Third, commercial teams should design evidence-generation plans that include real-world data collection, health economic modelling, and outcomes-based contracting options to address payer concerns about long-term value. Engaging key opinion leaders and multidisciplinary treatment centers early can facilitate guideline inclusion and appropriate uptake. Fourth, optimizing patient support and adherence programs-particularly for oral and outpatient-administered therapeutics-will drive persistence and outcomes, requiring integration with digital tools and specialty pharmacy networks. Finally, companies should consider flexible pricing and access strategies that reflect regional affordability constraints and promote equitable access, leveraging tiered contracting, compassionate use frameworks, and strategic partnerships with public and non-profit stakeholders. Taken together, these actions create a pragmatic road map for translating scientific advances into sustainable clinical and commercial impact.

Transparent research methodology combining literature review, expert input, and cross-functional evidence integration to support actionable conclusions and decision-making

The research approach underpinning this analysis combines systematic literature synthesis, expert interviews, and cross-functional evidence triangulation to ensure robust and actionable insights. Peer-reviewed clinical data, regulatory guidance documents, and public health advisories were reviewed to anchor clinical and regulatory interpretations. In addition, primary qualitative inputs from clinicians, pharmacoeconomists, supply-chain specialists, and diagnostic developers informed practical considerations around implementation, patient pathways, and reimbursement dynamics.

Methodologically, the study emphasizes evidence integration across preclinical mechanistic understanding, clinical trial outcomes, and real-world practice patterns. Analytical techniques included comparative therapeutic class assessment, scenario planning for supply-chain contingencies, and qualitative valuation of commercial models. Care was taken to validate assumptions through subject matter expert workshops and to cross-check policy interpretations with publicly available regulatory communications. Limitations include the rapidly evolving nature of clinical evidence and policy environments, which the methodology addresses by recommending periodic updates and staged deep dives tied to major regulatory or clinical inflection points.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and payer-aligned evidence strategies to achieve durable patient impact

In conclusion, lung cancer therapeutics stand at a juncture where scientific momentum must be matched by operational dexterity and stakeholder-aligned value demonstration. Advances in molecular targeting, immuno-oncology, and diagnostics have expanded therapeutic possibilities, yet commercialization success will hinge on the ability to translate those advances into accessible, sustainable care pathways. Supply-chain disruptions and trade policy shifts have underscored the importance of resilience planning, while payer expectations increasingly demand comprehensive real-world evidence and outcomes-focused contracting.

Looking forward, stakeholders who integrate biomarker-driven development with flexible manufacturing, region-specific access strategies, and payer-oriented evidence plans will be best positioned to convert clinical innovation into meaningful patient impact. By maintaining close collaboration across clinical, regulatory, commercial, and supply-chain disciplines, organizations can navigate complexity and accelerate the translation of promising therapies into standard-of-care options that improve outcomes for patients with lung cancer.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of immunotherapy indications exploring novel checkpoint targets beyond PD-1 and PD-L1 in lung cancer
• 5.2. Integration of AI-driven radiomics and genomics for predictive biomarker identification in lung cancer therapy
• 5.3. Emerging bispecific antibody approaches targeting two oncogenic pathways in NSCLC treatment
• 5.4. Incorporation of liquid biopsy assays for personalized monitoring of therapeutic response in lung cancer
• 5.5. Development of novel KRAS G12C inhibitors and combination regimens to overcome resistance in NSCLC
• 5.6. Advancements in inhalable nanocarrier-based drug delivery systems for targeted lung cancer therapy
• 5.7. Growing emphasis on EGFR exon 20 insertion mutation therapies and clinical trial outcomes in NSCLC
• 5.8. Adoption of real-world evidence frameworks to accelerate regulatory approvals in lung cancer treatment pathways
• 5.9. Emergence of cellular therapies including TCR-T and NK cell approaches for advanced lung cancer management
• 5.10. Focus on overcoming resistance mechanisms in targeted and immunotherapy treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Therapeutics Market, by Therapy Type

• 8.1. Chemotherapy
  • 8.1.1. Alkylating Agents
  • 8.1.2. Platinum-Based
  • 8.1.3. Taxanes
  • 8.1.4. Topoisomerase Inhibitors
• 8.2. Immunotherapy
  • 8.2.1. CTLA-4 Inhibitors
  • 8.2.2. PD-1 Inhibitors
  • 8.2.3. PD-L1 Inhibitors
• 8.3. Radiation Therapy
  • 8.3.1. Brachytherapy
  • 8.3.2. External Beam Radiation
  • 8.3.3. Stereotactic Body Radiation
• 8.4. Supportive Care
  • 8.4.1. Antiemetics
  • 8.4.2. Bone-Modifying Agents
  • 8.4.3. Hematopoietic Growth Factors
• 8.5. Surgery
• 8.6. Targeted Therapy
  • 8.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
  • 8.6.2. BRAF Inhibitors
  • 8.6.3. EGFR Inhibitors

9. Lung Cancer Therapeutics Market, by Mode Of Administration

• 9.1. Inhalation
• 9.2. Injectable
• 9.3. Oral

10. Lung Cancer Therapeutics Market, by Line Of Therapy

• 10.1. First-Line
• 10.2. Second-Line
• 10.3. Third-Line & Beyond

11. Lung Cancer Therapeutics Market, by Disease Stage

• 11.1. Stage I
• 11.2. Stage II
• 11.3. Stage III
• 11.4. Stage IV

12. Lung Cancer Therapeutics Market, by Prescription Status

• 12.1. Branded
• 12.2. Generic

13. Lung Cancer Therapeutics Market, by Distribution Channel

• 13.1. Offline Retail
• 13.2. Online Retail

14. Lung Cancer Therapeutics Market, by Cancer Type

• 14.1. Non-Small Cell Lung Cancer (NSCLC)
  • 14.1.1. Adenocarcinoma
  • 14.1.2. Large Cell Carcinoma
  • 14.1.3. Squamous Cell Carcinoma
• 14.2. Small Cell Lung Cancer (SCLC)

15. Lung Cancer Therapeutics Market, by End User

• 15.1. Ambulatory Infusion Centers
• 15.2. Cancer Centers
• 15.3. Homecare Settings
• 15.4. Hospitals

16. Lung Cancer Therapeutics Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Lung Cancer Therapeutics Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Lung Cancer Therapeutics Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Share Analysis, 2024
• 19.2. FPNV Positioning Matrix, 2024
• 19.3. Competitive Analysis
  • 19.3.1. AbbVie Inc.
  • 19.3.2. Amgen Inc.
  • 19.3.3. Astellas Pharma Inc.
  • 19.3.4. AstraZeneca PLC
  • 19.3.5. Bayer AG
  • 19.3.6. Boehringer Ingelheim International GmbH
  • 19.3.7. Johnson & Johnson Services, Inc.
  • 19.3.8. Merck & Co., Inc.
  • 19.3.9. Novartis AG
  • 19.3.10. Pfizer Inc.
  • 19.3.11. Sanofi S.A
  • 19.3.12. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 35. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 36. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 292. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 298. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILL